1. Home
  2. SUPX vs TLSI Comparison

SUPX vs TLSI Comparison

Compare SUPX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super X AI Technology Limited Ordinary Shares

SUPX

Super X AI Technology Limited Ordinary Shares

N/A

Current Price

$5.23

Market Cap

273.3M

Sector

N/A

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$2.42

Market Cap

250.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUPX
TLSI
Founded
2021
2010
Country
Singapore
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.3M
250.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SUPX
TLSI
Price
$5.23
$2.42
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $10.00
AVG Volume (30 Days)
★ 254.5K
192.8K
Earning Date
11-24-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $45,151,000.00
Revenue This Year
N/A
$14.10
Revenue Next Year
N/A
$37.87
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 53.41
52 Week Low
$4.11
$2.20
52 Week High
$49.99
$7.95

Technical Indicators

Market Signals
Indicator
SUPX
TLSI
Relative Strength Index (RSI) 39.51 23.71
Support Level $4.11 $2.20
Resistance Level $7.40 $4.35
Average True Range (ATR) 0.60 0.31
MACD -0.03 -0.09
Stochastic Oscillator 46.12 6.72

Price Performance

Historical Comparison
SUPX
TLSI

About SUPX Super X AI Technology Limited Ordinary Shares

Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: